Updates in Metastatic Colorectal Cancer

Presented by:
Alan P. Venook
Search for other papers by Alan P. Venook in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 23: Issue Supplement
Online Publication Date:
27 May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.5017
Restricted access

Colorectal cancer is a heterogeneous disease, with tumor location and microsatellite instability status influencing patient outcomes. Complicating treatment decisions is the presence of liver metastases, which present both an obstacle and an opportunity, as they can hinder the effectiveness of immunotherapy but may be addressed by both existing and emerging therapies. Agents targeting BRAF and HER2 aberrations as well as biomarkers, such as circulating tumor DNA and DPD, offer potential for more personalized approaches to treatment. The current NCCN Guidelines provide evidence-based recommendations for the management of colorectal cancer and reflect ongoing developments in the therapeutic landscape.

Disclosures: Dr. Venook has disclosed serving as a scientific advisor for Amgen Inc., Bristol Myers Squibb, Exact Sciences Corp., Exelixis, Inc., GSK, Intera Oncology, and Pfizer Inc.

Correspondence: Alan P. Venook, MD, UCSF Helen Diller Family Comprehensive Cancer Center, 1450 3rd Street, HD 376, Box 3111, San Francisco, CA 94143. Email: alan.venook@ucsf.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Piedbois P, Buyse M, Rustum Y, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate by the advanced colorectal cancer meta-analysis project. J Clin Oncol 1992;10:896–903.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;317:2392–2401.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Bond MJG, Bolhuis K, Loosveld OJL, et al. First-Line systemic treatment for initially unresectable colorectal liver metastases: post hoc analysis of the CAIRO5 randomized clinical trial. JAMA Oncol 2025;11:36–45.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Benson AB, Venook AP, Adam M, et al. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1.2025. Accessed March 24, 2025. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Benson AB, Venook AP, Adam M, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2025. Accessed March 24, 2025. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    André T, Elez E, Lenz HJ, et al. First results of nivolumab (NIVO) plus ipilimumab vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW. Presented at the 2025 ASCO Gastrointestinal Cancers Symposium; January 23–25, 2025; San Francisco, California. Abstract LBA143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Meijerink MR, van der Lei S, Dijkstra M, et al. Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): an international, multicenter, phase III randomized controlled trial. Presented at the 2024 ASCO Annual Meeting; May 31–June 4, 2024 ; Chicago, Illinois . Abstract LBA3501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Mendiratta-Lala M, Wiggermann P, Pech M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology 2024;312:e233051.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Adam R, Piedvache C, Chiche L, et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 2024;404:1107–1118.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Bullock AJ, Schlechter BL, Fakih MG, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med 2024;30:2558–2567.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med 2025;31:901–908.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 2024;25:1147–1162.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Nowak JA, Shi Q, Twombly T, et al. Prognostic and predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: findings from CALGB (Alliance)/SWOG 80702. Presented at the ASCO Gastrointestinal Cancers Symposium; January 23–25, 2025 ; San Francisco, California . Abstract LBA14.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    US Food & Drug Administration. Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment. January 24, 2025. Accessed March 31, 2025. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Abstract
Print Publication Date:
01 May 2025
Online Publication Date:
27 May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 561 562 561
PDF Downloads 288 288 288
EPUB Downloads 0 0 0